Does This Man Care More About Your Health Than You Do?
MANCHESTER, N.H., Sep. 26, 2013 /PRNewswire/ -- You may not think twice before you scarf down or imbibe your sugar-laden foods or beverages—that yummy cookie, that full-calorie soda, that sugar-laden salad dressing. But one man would head you off at the pass if he could. He believes refined sugar—anything made of simply carbohydrates—is one of the worst things you could eat, and that the purveyors of such food and drink are doing us harm. Of course he's not alone in what some might consider a quixotic quest. Unlike most, he's putting his money where his mouth is, actively doing something to help us undo what we've done to ourselves.
That intensely focused man is David Platt, and the company he founded is Boston Therapeutics, Inc., based in Manchester, NH. As CEO of this innovative pharmaceutical company, which is working on the development and commercialization of complex carbohydrate compounds, especially for people with diabetes, Platt's Holy Grail is to help people moderate their blood glucose levels after carbohydrate-rich meals. Carbohydrates are converted to glycogen during digestion, and are either used immediately for energy, or stored in the muscles and liver to be used for energy later. Simple carbohydrates raise blood sugar much faster and higher than healthy complex-carbohydrate foods.
Currently the company is working on a chewable, locally acting complex carbohydrate-based compound. This compound, which is called PAZ320, has been clinically shown in early studies to cut post-meal glucose elevation almost in half. Boston Therapeutics set out to make one molecule that would block all of the enzymes that participate in the digestion of sugar in the intestine. The proprietary polysaccharide—known as a carbohydrate hydrolyzing enzyme inhibitor (CHEI)—is designed to be taken before meals, and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.
PAZ320 will soon be tested in Phase II and Phase III clinical trials. The trials follow a Phase II study of PAZ320 last year at Dartmouth-Hitchcock Medical Center in Lebanon, NH that showed that 45 percent of patients responded to PAZ320 with a 40 percent reduction of post-meal glucose in the blood.
For the 25.8 million children and adults in the United States with diabetes who must keep their blood sugar in an acceptable range, this is great news. "Hopefully, people will begin to make wiser choices in what they eat and drink," Platt says. "Meanwhile, what we offer will ideally be proven to make a difference in how bodies process what is actually consumed."
For more information, visit www.bostonti.com.
Contact: Laura Radocaj, Dian Griesel Int'l. 212.825.3210
SOURCE Boston Therapeutics, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article